Background: The iStent (Glaukos Corporation; Laguna Hills, CA, USA) is one of the minimally invasive glaucoma devices. It can be inserted at the time of phacoemulsification or as a stand-alone procedure to lower the intraocular pressure (IOP).
Objective: Our aim was to conduct a systematic review and meta-analysis comparing the effect of iStent insertion at the time of phacoemulsification with phacoemulsification alone in patients with ocular hypertension or open-angle glaucoma.
Methods: We searched EMBASE, MEDLINE (OVID and PubMed), CINAHL, and Cochrane Library for articles published between 2008 and June 2022 (PRISMA 2020 for the checklist). Studies comparing the IOP-lowering effect of iStent with phacoemulsification versus phacoemulsification alone were included. The endpoints were IOP reduction (IOPR) and the mean reduction in the number of glaucoma drops. A quality-effects model was used to compare both surgical groups.
Results: Ten studies were included, reporting on 1,453 eyes. Eight hundred fifty three eyes had the combined iStent and phacoemulsification, and 600 eyes underwent phacoemulsification alone. IOPR was higher in the combined surgery at of 4.7 ± 2 mm Hg compared to 2.8 ± 1.9 mm Hg in phacoemulsification alone. A greater decrease in postoperative eye drops was noted in the combined group having a decrease of 1.2 ± 0.3 eye drops versus of 0.6 ± 0.6 drops in isolated phacoemulsification. The quality effect model showed an IOPR weighted mean difference (WMD) of 1.22 mm Hg (confidence interval [CI]: [-0.43, 2.87]; Q = 315.64; p < 0.01; I2 = 97%) and decreased eye drops WMD 0.42 drops (CI: [0.22, 0.62]; Q = 42.6; p < 0.01; I2 = 84%) between both surgical groups. Subgroup analysis shows that the new generation iStent may be more effective in reducing IOP.
Conclusion: iStent has a synergetic effect with phacoemulsification. The reduction of IOP and glaucoma eye drops was higher when iStent is combined with phacoemulsification compared with isolated phacoemulsification.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1159/000531077 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Efficacy and safety of preservative-free anti-glaucomatous eye drops (dorzolamide/timolol) in ocular hypertension and/or glaucoma.
Int Ophthalmol
January 2025
Chairman and Professor of Ophthalmology, Kasr Alainy Faculty of Medicine, Cairo University, Giza, Egypt.
Purpose: This study evaluated the efficacy, safety, and tolerability of a single-dose, preservative-free (PF) Dorzolamide/Timolol combination (Twinzol-SDU).
Methods: A 3-month single-arm, multicenter, prospective cohort study was conducted in Egypt between January 2021 and October 2022 on previously diagnosed and controlled patients with ocular hypertension and/or glaucoma. Efficacy was assessed using the change in intraocular pressure (IOP) after 6 and 12 weeks.
Controlled PVA Release from Chemical-Physical Interpenetrating Networks to Treat Dry Eyes.
ACS Omega
January 2025
Centre for Ocular Research & Education (CORE), School of Optometry & Vision Science, University of Waterloo, 200 University Avenue West, Waterloo N2L 3G1, ON, Canada.
Dry eye disease is becoming increasingly prevalent, and lubricating eye drops, a mainstay of its treatment, have a short duration of time on the ocular surface. Although there are various drug delivery methods to increase the ocular surface residence time of a topical lubricant, the main problem is the burst release from these delivery systems. To overcome this limitation, herein, a chemical-physical interpenetrating network (IPN) was fabricated to take control over the release of poly(vinyl alcohol) (PVA), a well-known therapeutic agent used to stabilize tear film, from gelatin methacrylate (GelMA) hydrogels.
View Article and Find Full Text PDFA Modified Polydopamine Nanoparticle Loaded with Melatonin for Synergistic ROS Scavenging and Anti-Inflammatory Effects in the Treatment of Dry Eye Disease.
Adv Healthc Mater
January 2025
State Key Laboratory of Ophthalmology, Zhongshan Ophthalmic Center, Guangdong Provincial Key Laboratory of Ophthalmology Visual Science, Sun Yat-sen University, Guangzhou, 510060, China.
Dry eye disease (DED) is a multifaceted ocular surface disorder that significantly impacts patients' daily lives and imposes a substantial economic burden on society. Oxidative stress, induced by the overproduction of reactive oxygen species (ROS), is a critical factor perpetuating the inflammatory cycle in DED. Effectively scavenging ROS is essential to impede the progression of DED.
View Article and Find Full Text PDFChoroidal thickness under pilocarpine versus cyclopentolate.
Sci Rep
January 2025
Privatpraxis Prof Jonas und Dr Panda-Jonas, Heidelberg, Germany.
Bruch´s membrane (BM) is firmly connected posteriorly to the optic nerve head through the peripapillary choroidal border tissue, and anteriorly through the longitudinal ciliary muscle to the scleral spur. We assessed, whether a difference in the contractile state of the ciliary muscle influences the position of the posterior BM by lifting the posterior BM pole, i.e.
View Article and Find Full Text PDFRole of caffeine in slowing progression of myopia: 1-year results from a prospective, longitudinal clinical trial.
Asia Pac J Ophthalmol (Phila)
January 2025
School of Optometry and Vision Science, University of New South Wales, Sydney, Australia.
Purpose: To determine the role of topical caffeine in slowing progression of myopia, both as a standalone treatment and in combination with atropine.
Methods: In a prospective, randomized, dispensing clinical trial, 96 children with myopia, aged 6-13 years, spherical equivalent (SE) from -0.50 diopters (D) to -6.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!